Mexico's New Medical Device Labeling Standard: COFEPRIS NOM-137-SSA1-2025 Compliance by 2027

Japan PMDA SaMD Guidance: Key Changes from the June 2026 Update

On June 5, 2026, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) updated its core guidance for Software as a Medical Device (SaMD). This episode breaks down the key changes, including new requirements for AI/ML validation, heightened cybersecurity expectations, and clarified classification rules. We explore how these updates will impact regulatory strategies, submission timelines, and what practical steps SaMD manufacturers should take to ensure compliance and successful market access in Japan. Key Questions: - What specific changes did the PMDA make to its SaMD guidance on June 5, 2026? - How do these updates affect the classification of software medical devices in Japan? - What are the new expectations for AI and machine learning (AI/ML) SaMD validation? - What does the updated guidance say about cybersecurity requirements for SaMD? - How will these changes impact submission timelines for the Japanese market? - Who is most affected by this PMDA update? - What practical steps should regulatory teams take right now to prepare? - How does this update fit into Japan's broader digital health strategy? Sources: - https://www.pmda.go.jp/english/whatsnew/2026.html - https://www.pmda.go.jp/english/review/outline/devices/0007.html How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, developing efficient regulatory strategies and using advanced AI to compile and manage technical dossiers for submission. Our services cover the entire product lifecycle, from market selection to post-market surveillance, ensuring your products remain compliant with evolving regulations like the PMDA's SaMD guidance. With a global reach and local expertise, we help startups, scaleups, and multinational enterprises navigate complex regulatory landscapes. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

FDA AI Medical Device Guidance 2026: New Rules for Transparency and Lifecycle Management

This episode breaks down the US FDA's new draft guidance on AI-enabled medical device software, released on June 6, 2026. We explore the FDA's stricter requirements for algorithm transparency, data provenance, risk management, and real-world performance monitoring. We discuss how these changes impact pre-market submissions and post-market obligations for manufacturers and highlight the critical opportunity to provide feedback before the public comment period closes on August 5, 2026. Key Questions: - What are the four key areas of change in the FDA's 2026 AI medical device guidance? - How does the new guidance change expectations for algorithm transparency and 'black box' AI? - What is data provenance and why is it now a critical part of FDA submissions? - What new AI-specific risks must manufacturers now include in their risk management files? - How will real-world performance monitoring requirements affect post-market responsibilities? - Who is impacted by this new draft guidance? - What is the deadline for submitting public comments to the FDA? - What immediate steps should regulatory and quality teams take to prepare? Sources: - https://www.bespokementis.com/news/fda-issues-2026-guidance-clarifies-ai-medical-device-compliance How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies navigating complex requirements like the FDA's new AI guidance. Our experts help you develop compliant regulatory strategies, compile robust technical dossiers, and implement effective quality management systems for AI-enabled devices. We combine local expertise with advanced AI tools to streamline global market access and ensure you meet evolving standards for algorithm transparency, data governance, and post-market surveillance. For support with your US market access strategy or global expansion, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI-powered regulatory tools and global device database at https://pureglobal.ai.

FDA Payor Communications Guidance 2026: What Medical Device Manufacturers Need to Know

The US FDA's June 3, 2026 draft guidance on manufacturer communications with payors marks a significant policy shift for the medical device industry. This episode breaks down how the guidance extends the safe harbor for sharing Healthcare Economic Information (HCEI) to medical devices and incorporates the Pre-Approval Information Exchange (PIE) Act. We discuss the practical implications for market access, what constitutes 'competent and reliable scientific evidence,' and the steps regulatory and commercial teams should take now to align with the FDA's new framework for communicating with payors about both approved and unapproved products. Key Questions: - What is the FDA's new draft guidance on payor communications issued on June 3, 2026? - How does this guidance extend the HCEI safe harbor to medical devices? - What does the incorporation of the Pre-Approval Information Exchange (PIE) Act mean for manufacturers? - Who is considered a 'payor' under this new framework? - What kind of information can be shared about unapproved devices or unapproved uses? - What constitutes 'competent and reliable scientific evidence' for HCEI claims? - How should medical device companies update their communication strategies with payors? - What practical steps should regulatory and commercial teams take now? Sources: - https://www.kslaw.com/news-and-insights/fda-issues-new-draft-guidance-addressing-communications-with-payors - https://www.arnoldporter.com/en/perspectives/advisories/2026/06/fda-proposes-revised-payor-communications How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, helping you navigate complex landscapes like the US FDA's evolving requirements. Our experts develop efficient regulatory strategies for market access, leveraging deep local knowledge to ensure your payor communications and technical dossiers meet all standards. We use advanced AI to compile and manage submissions, accelerating your path to market. Whether you need a US Agent, support with a 510(k) or PMA submission, or a comprehensive global regulatory strategy, Pure Global is your partner. Learn more about our services at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

FDA 510(k) Exemption for Unclassified Devices: New June 2026 Guidance

The US FDA has released a new final guidance, effective June 4, 2026, exempting certain unclassified medical devices from 510(k) premarket notification. This episode explains what 'unclassified devices' are, how this policy streamlines their market access pathway, and the specific actions manufacturers should take to leverage this change while remaining compliant with FDA's General Controls. Key Questions: - What are 'unclassified' medical devices under FDA regulations? - Which specific device types are now exempt from 510(k) submission as of June 2026? - How does this new guidance impact the market entry strategy for these products? - What are 'General Controls' and why do they still apply to 510(k)-exempt devices? - Does this exemption mean manufacturers no longer need a quality management system? - What are the immediate, practical steps regulatory affairs teams should take in response to this guidance? - How can this change accelerate timelines and reduce costs for product development? - Where can I find the official list of newly exempted devices? Sources: - https://www.fda.gov/medical-devices/news-events-medical-devices/cdrh-new-news-and-updates How Pure Global can help: Pure Global helps MedTech and IVD companies accelerate global market access. Our experts can help you interpret new FDA guidance, determine the regulatory status of your devices, and develop an efficient US market entry strategy. We use advanced AI tools to compile technical dossiers and manage submissions, ensuring compliance while reducing your time to market. Whether you're a startup or a multinational enterprise, our end-to-end solutions, including local representation and post-market surveillance, provide a streamlined path for your products. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

EU AI Act & Medical Devices: Deadline Extended to 2028 for High-Risk Systems

The European Union has extended the compliance deadline for the AI Act for high-risk medical devices and IVDs already regulated by the MDR and IVDR. A provisional agreement on the Digital Omnibus package has postponed the application date by two years to August 2, 2028. This episode explores what this delay means for manufacturers, how it impacts compliance strategies, and the practical steps regulatory and quality teams should take to prepare for the eventual implementation. Key Questions: - What is the new AI Act compliance deadline for high-risk medical devices? - How does the Digital Omnibus package affect MDR and IVDR manufacturers? - Why was the original 2026 deadline for the AI Act extended? - What does this extension mean for your AI governance and QMS integration strategy? - Should you pause your AI Act compliance activities because of the delay? - How do the requirements of the AI Act and the MDR/IVDR overlap? - What practical steps should regulatory teams take over the next two years? - How will harmonized standards for AI in medical devices evolve before 2028? Sources: - https://www.medtech-europe.org/news/medtech-europe-reaction-to-the-provisional-agreement-on-the-digital-omnibus-on-ai/ - https://www.morganlewis.com/pubs/2026/05/recent-eu-and-uk-medical-devices-developments-eu-mdr-ivdr-eu-ai-act-uk-medical-devices-regime - https://www.consilium.europa.eu/en/press/press-releases/2026/05/07/artificial-intelligence-council-and-parliament-agree-to-simplify-and-streamline-rules/ How Pure Global can help: Pure Global provides comprehensive regulatory consulting for MedTech and IVD companies, streamlining global market access. We develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative in over 30 markets. Our experts help you navigate complex requirements like the EU AI Act and MDR/IVDR, ensuring your products remain compliant from initial registration through post-market surveillance. Leverage our advanced AI tools and global expertise to accelerate your market entry. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, and explore our free AI tools and database at https://pureglobal.ai.